Echo-T

Echo-T is Cellistic's iPSC-derived T-cell therapy manufacturing platform. It provides a pre-established platform to support the development and GMP manufacturing of iPSC-derived T-cell therapies, taking immune cell therapy programs from concept through clinical manufacturing.

Echo-T produces CD8, CD4, CD4/8 double-positive, and Treg cell types from a single iPSC-derived platform.

Echo-T's iPSC-derived CD8 and CD4 T cells can serve as a starting cell type for engineered cell therapy programs, including CAR-T and TCR-T.

Donor-derived manufacturing — whether autologous or healthy-donor allogeneic — is constrained by variability in starting material, limited scalability, and reduced control over downstream product design. Echo-T's iPSC-derived approach starts from a single, renewable, engineerable cell bank, which supports process standardization, defined cell outputs, and industrialized scale-up.

Yes. Echo-T is built on a single master iPSC line, from which CD4 and CD8 T cells are produced at scale in controlled bioreactor conditions, removing reliance on variable donor material for each manufacturing batch.

Yes. Echo-T runs on a feeder-free, defined differentiation and expansion process, without scale-limiting cell sorting steps. 

Echo-T platform is optimized for differentiation towards either αβ T cells (CD4, CD8) orTregs, each supported by dedicated phenotypic and functional characterization data. 

Echo-T follows a controlled, GMP-ready workflow organized into defined unit operations:

1. iPSC amplification

2. Hemogeneic endothelium

3. HSC (can be cryopreserved)

4. T cell differentiation

5. T cell activation and expansion

6. Automated fill and finish and cryopreservation

7. Drug product release